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Abstract: Objective The soluble guanylate cyclase stimulator riociguat is approved for the treatment of
adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic
thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE
Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor
the long-term safety of riociguat in clinical practice. Methods EXPERT was an international, multicenter,
prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients
were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat
treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded
using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version
21.0, collected during routine clinic visits and collated via case report forms. Results In total, 956 patients
with CTEPH were included in the analysis. The most common AEs in these patients were peripheral
edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia
(5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and
syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were
low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic
Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). Conclusion Data from
EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent
with the known safety profile of the drug, and no new safety concerns were identified.
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Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of 
adult patients with pulmonary arterial hypertension (PAH) and inoperable or 
persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following 
Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary 
hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in 
clinical practice. 
Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-
interventional cohort study of patients treated with riociguat. Patients were followed for at 
least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat 
treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events 
(SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System 
Organ Classes version 21.0, collected during routine clinic visits and collated via case report 
forms. 
Results: In total, 956 patients with CTEPH were included in the analysis. The most common 
AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right 
ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs 
were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). 
Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low 
and comparable to those in the long-term extension study of riociguat (Chronic 
Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial 
[CHEST-2]). 
Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in 
routine practice was consistent with the known safety profile of the drug, and no new safety 













Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal condition 
characterized by obstruction of the pulmonary vasculature by residual organized thrombi 
resulting in increased pulmonary vascular resistance (PVR), progressive vascular 
remodeling and pulmonary hypertension (PH), and subsequently right ventricular (RV) failure 
[1–4].  
The treatment of choice in CTEPH is pulmonary endarterectomy (PEA), which potentially 
normalizes hemodynamics [5–7]. Up to 40% of patients are inoperable, however, and up to 
51% exhibit persistent or recurrent CTEPH after PEA [5–13].  
Riociguat is a first-in-class soluble guanylate cyclase stimulator recommended in 
European Respiratory Society/European Society of Cardiology guidelines for the treatment 
of patients with inoperable CTEPH or persistent/recurrent CTEPH after surgery [1]. Its 
efficacy and tolerability have been demonstrated in clinical trials [14, 15]. Agents that have 
been approved for pulmonary arterial hypertension (PAH) include prostacyclin analogs, 
endothelin receptor antagonists (ERAs), and phosphodiesterase type 5 inhibitors (PDE5i). 
With the exception of treprostinil in selected patients, these are not licensed for use in the 
treatment of patients with CTEPH, but can be administered off-label. Balloon pulmonary 
angioplasty (BPA) is a potentially effective option for selected inoperable patients [1, 16]. 
EXPosurE Registry RiociguaT in patients with PH (EXPERT) was a prospective, non-













2.1. Study design  
EXPERT (NCT02092818) was an international, multicenter, prospective, uncontrolled, 
non-interventional cohort study in patients treated with riociguat in 28 countries. The design 
is described in detail elsewhere (Hoeper et al., submitted). EXPERT was linked with the 
Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension 
(COMPERA [https://compera.org/]), one of the largest global academic PH registries. This 
was consistent with guidance from regulatory authorities to use existing registries. EXPERT 
was conducted in accordance with good pharmacovigilance practices and was not 
requested, but was accepted, by the European Medicines Agency for the collection of 
additional long-term post-approval data on riociguat. 
Patients were followed for 1 to 4 years from enrollment (including post-treatment safety 
follow-up) during a recruitment period of 3 years or until 30 days after stopping riociguat 
treatment. Data—including patient demographics, disease characteristics, riociguat dosing, 
hemodynamic parameters, changes in treatment, biomarkers, laboratory variables, adverse 
events (AEs) and serious adverse events (SAEs)—were collected at baseline and during 
routine clinical follow-up visits approximately every 3 to 6 months. Data were collected using 
a case report form (CRF) based on the COMPERA CRF, extended to obtain riociguat safety 
data. 
2.2. Patients 
Patients who started treatment or were already being treated with riociguat were eligible 
for inclusion. Patients with disease duration ≥ 6 months were defined as prevalent, and 
those diagnosed within < 6 months of enrollment were defined as incident. Patients were 
defined as riociguat-pretreated if they had been receiving riociguat for ≥ 3 months before 











months before entry. Riociguat-newly treated patients were therefore not necessarily 
incident patients and could have received PAH-approved therapy before riociguat. Newly 
treated patients were further categorized as switched or non-switched. Switched patients 
were newly treated patients who had stopped prior therapy ≤ 10 days before commencing 
riociguat.  
 
2.3. Safety assessments 
The primary safety outcomes were AEs and SAEs, coded using Medical Dictionary for 
Regulatory Activities (MedDRA) preferred terms and System Organ Classes version 21.0. 
Secondary safety outcomes included AEs and SAEs of special interest (hypotension and 
hemoptysis/pulmonary hemorrhage). This report focuses on AEs and SAEs occurring during 
the treatment phase (onset date ≤ 2 days after the most recent dose of riociguat). An AE 
was considered serious if it: resulted in death, was life-threatening, required inpatient 
hospitalization or prolongation of hospitalization (with specific exceptions, defined in the 
protocol), resulted in persistent or significant disability or incapacity, was a congenital 
abnormality or birth defect, or was medically important. AEs and SAEs were classified as 
drug-related by according to the investigator’s judgment. Deaths were analyzed in terms of 
all SAEs with a fatal outcome with onset during the treatment phase and the post-treatment 
phase (onset date > 2 days after discontinuation until the end of 30-day safety follow-up). 
2.4. Statistical methods and populations analyzed 
EXPERT was an observational study. All variables and outcomes, including comparisons 
between predefined groups (such as newly treated versus pretreated patients and prevalent 
versus incident patients) were analyzed descriptively. Statistical analyses of these 
comparisons were not performed because they would be of limited value without adjustment 
for differences between the groups. All analyses were performed with SAS 9.3. Categorical 











statistics (mean ± standard deviation [SD], median, and minimum–maximum range). The 
evaluable population consisted of all enrolled patients who did not withdraw consent and had 
received at least one dose of riociguat with dosing data available. Summary statistics and 
changes from baseline were calculated for 6-minute walking distance (6MWD), World Health 
Organization Functional Class (WHO FC), Borg Dyspnea Index, EuroQoL 5-dimensional 
Visual Analog Score (EQ-5D VAS), hemodynamic parameters, and biomarkers. This paper 
describes the results in patients with CTEPH. Results in patients with PAH are described 
separately (Hoeper et al., submitted). 
 
Results 
3.1. Patient disposition 
The evaluable population with CTEPH consisted of 956 patients of whom 537 (56.2%) 
were riociguat-pretreated and 419 (43.8%) were riociguat-newly treated. Approximately 86% 













Fig. 1. Patient disposition. 
CTEPH, chronic thromboembolic pulmonary hypertension. The numbers and percentages 
refer to the total CTEPH population enrolled (n = 969). 
Chart shows primary reason for not completing per protocol.  
aOther reasons for discontinuation are shown in supplementary Table 1. 
3.2. Demographics and baseline characteristics 
The mean age of the patients was 66.3 ± 13.7 years; 570 patients (59.6%) were women. 
CTEPH was prevalent in 713 patients (74.6%), incident in 197 (20.6%), and unknown in 46 
(4.8%). At baseline, riociguat was administered in combination with other PH-approved 
therapy in 198 patients (20.7%): with ERAs in 170 (17.8% [bosentan, 7.0%; macitentan, 
7.0%; and ambrisentan, 3.8%]), prostanoids in 9 (0.9% [iloprost, 0.6%; intravenous 
treprostinil, 0.2%; and intravenous epoprostenol, 0.1%]), and both an ERA and prostanoid in 
19 (2.0%). No patient received concomitant PDE5i. At Visit 6 (month 33−<39), 27.9% of 
patients were receiving combination therapy. In total, 901 patients (94.2%) had at least one 
comorbidity. Other baseline demographics are shown in Table 1. The operability status of 
the patients is shown in Figure 2.  
 
Table 1 
Baseline demographics and disease characteristics in the total CTEPH population (n = 956).  
Characteristic Mean ± SD or n (%) 
Age, years 66.3 ± 13.7 
Age group, years 
< 65 





BMI, kg/m² 28.6 ± 15.2 
BMI category, kg/m² 
< 18.5 
18.5 to < 25 

























Age at initial PH diagnosis, years 62.7 ± 14.5 
Median (IQR) disease duration, years 2.1 (0.7−4.9) 
WHO FC, % (I/II/III/IV/unknown) 4.0/38.2/50.1/3.0/4.7 
BNP, pg/mL (median, range) 131 (5−5844) (n = 148) 
NT-proBNP, pg/mL (median, range) 602 (16−177 759) (n = 540) 
6MWD, m 365 ± 128 
6MWD 
< 320 ma 
≥ 320 m 
< 380 m 








EQ-5D VAS 62.3 ± 20.6 (n = 229) 
Borg Dyspnea Index 3.8 ± 2.2 (n = 701) 
mPAP, mmHg 43.0 ± 11.5 (n = 850) 
PVR, dyn·s·cm−5 652 ± 502 (n = 767) 
PAWP, mmHg 11.1 ± 5.0 (n = 809) 
Cardiac index, L/min/m2 2.8 ± 4.4 (n = 756) 
RAP, mmHg 9.0 ± 5.6 (n = 710) 
SvO2 (%) 63.7 ± 9.2 (n = 613) 




6.9 ± 1.4 (n = 934) 
7.5 (1.5−7.5) (n = 934) 
Riociguat median daily dose at initial 
study visit (mg)  
≤ 2.5 
> 2.5 to 4.5 
> 4.5 to 6 









Concomitant CCB 22 (2.3) 
Concomitant anticoagulation therapy 
        Oral anticoagulation 
               Vitamin K antagonist 
               Direct oral anticoagulant 
               Other oral anticoagulationb 

















Concomitant antiplatelet agents 44 (4.6) 
Comorbidity 






Coronary heart disease 
Obstructive sleep apnea 













6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide; 
CCB, calcium channel blocker; CTEPH, chronic thromboembolic pulmonary hypertension; 
EQ-5D VAS, EuroQoL 5-dimensional Visual Analog Score; IQR, interquartile range; mPAP, 
mean pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic 
peptide; PAWP, pulmonary artery wedge pressure; PEA, pulmonary endarterectomy; PH, 
pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; 
SD, standard deviation; SvO2, saturated venous oxygen; WHO FC, World Health 
Organization functional class. 
Data are mean ± SD or number (%) unless otherwise stated. 
Results are for all patients (n = 956) unless otherwise stated. 
aThresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the 
time indicating good or poor prognosis in PAH. 












Fig. 2. Operability status. 
BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary 
hypertension; PEA, pulmonary endarterectomy. 
Persistent CTEPH after PEA or BPA were determined by the investigator. 
 
3.3. Riociguat safety 
3.3.1. Total CTEPH population 
In the total population with CTEPH, the median (range) duration of observation and 
riociguat treatment was 504.0 (0.0−1367.0) days and 493.5 (0.0−1367.0) days, respectively. 
In total, 615 patients (64.3%) experienced AEs and 365 (38.2%) experienced SAEs. These 
events were considered drug-related by the investigator in 148 (15.5%) and 34 (3.6%) 
patients, respectively. The most common AEs and SAEs are shown in Table 2. 
Discontinuation due to AEs and SAEs occurred in 55 patients (5.8%) and 38 patients (4.0%), 
respectively. The most common AEs or SAEs leading to discontinuation are shown in 
supplementary Table 2. Safety data for patients according to use of riociguat as 
monotherapy or in combination with other PAH-approved drugs are shown in supplementary 











numerically higher with prostanoid-containing regimens (78.9–88.9% and 57.9–66.7%, 
respectively) than with riociguat monotherapy or riociguat + ERA (62.8–68.2% and 36.0–
44.1%, respectively), but the numbers of patients receiving prostanoids were small. 
 
Table 2 
Most common AEs and SAEs in the total CTEPH population (n = 956). 
AEsa n (%) 
Peripheral edema/edema 112 (11.7)b 
Dyspnea 81 (8.5) 
RV failure/cardiac failure 74 (7.7)c 
Dizziness 72 (7.5) 
Pneumonia 48 (5.0) 
SAEsd  
RV failure/cardiac failure 71 (7.4)e 
Pneumonia 39 (4.1) 
Dyspnea 34 (3.6) 
Syncope 24 (2.5) 
PHe 22 (2.3) 
AE, adverse event; CTEPH, chronic thromboembolic pulmonary hypertension; PH, 
pulmonary hypertension; RV, right ventricular; SAE, serious adverse event. 
 aPreferred-term AEs reported in ≥ 5% of patients. 
bIncluding peripheral edema in 73 patients (7.6%) and edema in 42 patients (4.4%). 
cIncluding RV failure in 61 patients (6.4%) and cardiac failure in 16 patients (1.7%). 
dPreferred-term SAEs reported in ≥ 2% of patients. 
eIncluding RV failure in 59 patients (6.2%) and cardiac failure in 15 patients (1.6%). 
ePreferred term for worsening of the condition. 
Note. Patients with peripheral edema/edema, or RV failure/cardiac failure could have both 
events. 
 
Hemorrhages were reported in 110 patients (11.5%) and serious hemorrhages in 57 
patients (6.0%). These events were considered by the investigator to be related to riociguat 
in nine (0.9%) and four patients (0.4%), respectively. Three patients (0.3%) discontinued 











epistaxis in 30 patients (3.1%) and hemoptysis in 26 patients (2.7%). The most common 
serious hemorrhages were hemoptysis in 16 patients (1.7%) and gastrointestinal 
hemorrhage in five patients (0.5%). Of all patients who experienced a hemorrhage, 78 were 
recorded as receiving a vitamin K antagonist (VKA) and 24 as receiving non-VKA oral 
anticoagulants (NOAC). Hemoptysis and pulmonary hemorrhage were considered AEs of 
special interest and are discussed further below. 
 
3.3.2. Safety in prevalent vs. incident patients 
A post hoc analysis compared prevalent patients (disease duration ≥ 6 months) (n = 713) 
with incident patients (diagnosed within < 6 months of enrollment) (n = 197) according to 
disease duration data available at baseline. Disease characteristics, including 6MWD and 
WHO FC, indicated a more severe disease status in incident patients compared with 
prevalent patients (data not shown). Median disease duration was 1.8 (range, 0.0−6.0) 
months in incident patients and 3.2 (range, 0.5−39.7) years in prevalent patients. AEs were 
reported in 471 prevalent patients (66.1%) and 119 incident patients (60.4%), and SAEs in 
276 (38.7%) and 73 (37.1%) prevalent and incident patients, respectively.  
3.3.3. Comparison between riociguat-pretreated and riociguat-newly treated patients 
 Compared with riociguat-pretreated patients, riociguat-newly treated patients had a 
numerically shorter disease duration, shorter 6MWD, a higher proportion of WHO FC III/IV 
disease, and a greater proportion of incident disease (Table 3). More than 90% of patients in 
both groups had at least one comorbidity. Approximately 89% of riociguat-pretreated 
patients and 83% of riociguat-newly treated patients completed the study (Figure 3). Of the 
riociguat-newly treated patients, 72 (17.2%) had switched from previous PAH-approved 
therapy: 65 (15.5%) from PDE5i, 5 (1.2%) from a prostanoid, and 12 (2.9%) from an ERA 














Fig. 3. Disposition of riociguat-pretreated and riociguat-newly treated patients with CTEPH. 
Chart shows primary reason for discontinuation. 
aOther reasons for not completing the study are listed in supplementary Table 1. 
 
Table 3 
Baseline demographics and disease characteristics of riociguat-pretreated and riociguat-
newly treated patients.  
 Riociguat-pretreateda 
 (n = 537) 
Riociguat-newly treatedb 
(n = 419) 
Age, years 65.9 ± 14.1 66.8 ± 13.3 
Age group, years, n (%) 
< 65 










Female sex, n (%) 337 (62.8) 233 (55.6) 
BMI, kg/m² 29.1 ± 19.5 28.0 ± 6.3 
BMI category, kg/m², n (%) 
< 18.5 
18.5 to < 25 


































Prevalent (disease duration ≥ 6 months), n (%) 
Incident (disease duration < 6 months)  







Age at initial PH diagnosis, years 61.6 ± 14.8 (n = 509) 64.2 ± 13.9 (n = 403) 
Median (IQR) PH disease duration, years 2.9 (1.5−5.6) 0.8 (0.2−4.0) 
Persistent CTEPH following PEA, n (%) 133 (24.8) 74 (17.7) 
Persistent CTEPH following BPA, n (%) 16 (3.0) 10 (2.4) 
WHO FC, % (I/II/III/IV/unknown) 5.6/45.1/43.6/2.8/3.0 1.9/29.4/58.5/3.3/6.9 
BNP, pg/mL (median, range) 107 (5−3560) (n = 79) 
171 (6−5844) 
(n = 69) 
NT-proBNP, pg/mL (median, range) 483 (16−177 759) (n = 320) 
813 (17−48 858) 
(n = 220) 
6MWD, m 382 ± 122 (n = 477) 341 ± 133 (n = 334) 
6MWD, n (%) 
< 320 mc 
≥ 320 m 
< 380 m 














EQ-5D VAS 63.6 ± 19.7 (n = 144) 60.1 ± 22.1 (n = 85) 
Borg Dyspnea Index 3.7 ± 2.2 (n = 403) 4.0 ± 2.3 (n = 298) 
mPAP, mmHg 43.3 ± 11.8 (n = 462) 42.8 ± 11.2 (n = 388) 
PVR, dyn·s·cm-5 675 ± 575 (n = 413) 626 ± 400 (n = 354) 
PAWP, mmHg 11.2 ± 5.0 (n = 436) 10.9 ± 4.9 (n = 373) 
Cardiac index, L/min/m2 2.8 ± 5.0 (n = 409) 2.7 ± 3.7 (n = 347) 
RAP, mmHg 9.3 ± 5.9 (n = 389) 8.6 ± 5.1 (n = 321) 
SvO2 (%) 63.6 ± 9.5 (n = 323) 63.9 ± 8.9 (n = 290) 




 7.1 ± 1.1 
7.5 (1.5−7.5) 
 
6.6 ± 1.6 (n = 397) 
7.5 (1.5−7.5) 
(n = 397) 
Riociguat median daily dose at initial study 
visit, mg, n (%) 
≤ 2.5 
> 2.5 to 4.5 
> 4.5 to 6 



































Riociguat combination therapye,f 
Riociguat + ERA 
            Riociguat + ambrisentan 
            Riociguat + bosentan 
            Riociguat + macitentan 
Riociguat + prostanoid 
 Riociguat + iloprost 
 Riociguat + intravenous treprostinil 
 Riociguat + intravenous epoprostenol 
Riociguat + ERA + prostanoid 
112 (20.9) 
    21 (3.9) 
   47 (8.8) 
   44 (8.2) 
6 (1.1) 
      3 (0.6) 
      2 (0.4) 
     1 (0.2) 
    16 (3.0) 
58 (13.8) 
   15 (3.6) 
    20 (4.8) 
    23 (5.5) 
3 (0.7) 
     3 (0.7) 
     0 (0.0) 
     0 (0.0) 
    3 (0.7) 
Concomitant CCB, n (%) 13 (2.4) 9 (2.1) 
Concomitant anticoagulation, n (%) 
Oral anticoagulation 
                 Vitamin K antagonist 
                 Direct oral anticoagulant 














Concomitant antiplatelet agents, n (%) 16 (3.0) 28 (6.7) 
Comorbidity, n (%) 





Coronary heart disease 
Diabetes mellitus 
Obstructive sleep apnea 
























6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide; 
BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, chronic 
thromboembolic pulmonary hypertension; EQ-5D VAS, EuroQoL 5-dimensional Visual 
Analog Score; ERA, endothelin receptor antagonist; IQR, interquartile range; mPAP, mean 
pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; 
PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PEA, 
pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular 
resistance; RAP, right atrial pressure; SD, standard deviation; SvO2, saturated venous 
oxygen; WHO FC, World Health Organization functional class. 
Data are mean ± SD or number (%), unless otherwise stated. 
aReceiving riociguat for ≥ 3 months before entry (n = 537 unless otherwise indicated). 











cThresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time 
indicating good or poor prognosis in PAH. 
dPatients receiving riociguat but no ERA or prostanoid. 
ePatients receiving riociguat + ERA or prostanoid or both. 
fNo patient received concomitant PDE5i during the study. 
gAs indicated by the investigator on the CRF. 
 
AEs were reported in 270 riociguat-newly treated patients (64.4%) and 345 riociguat-
pretreated patients (64.2%). SAEs were reported in 166 riociguat-newly treated patients 
(39.6%) and 199 riociguat-pretreated patients (37.1%). Numerically more AEs and SAEs in 
riociguat-newly treated patients were considered drug-related and led to drug discontinuation 
than in riociguat-pretreated patients (Table 4). The types of AEs and SAEs were generally 
similar between the two groups. The most common AEs or SAEs leading to discontinuation 
are shown in supplementary Table 4. Safety results in switched patients were generally 
similar to those in non-switched patients (data not shown). In riociguat-pretreated and 
riociguat-newly treated patients, AEs and SAEs were more frequent with combination 
therapy than with monotherapy (supplementary Table 5). 
 
Table 4 
Safety summary in riociguat-pretreated and riociguat-newly treated patients with CTEPH. 
 Riociguat-pretreateda (n 
= 537) 
Riociguat-newly treatedb 
(n = 419) 
AEs n (%) n (%) 
Any AE 345 (64.2) 270 (64.4) 
Most common AEsc n (%) n (%) 
Peripheral edema/edema 73 (13.6)d 39 (9.3)e 
Dyspnea 50 (9.3) 31 (7.4) 
Dizziness 42 (7.8) 30 (7.2) 
RV failure/cardiac failure 40 (7.4)f 34 (8.1)g 
Pneumonia 31 (5.8) 17 (4.1) 
Cough 27 (5.0) 16 (3.8) 
Hypotension 13 (2.4) 24 (5.7) 











Any drug-related AEh 53 (9.9) 95 (22.7) 
Discontinuation due to AE 21 (3.9) 34 (8.1) 
SAEs n (%) n (%) 
Any SAE 199 (37.1) 166 (39.6) 
Most common SAEsi n (%) n (%) 
RV failure/cardiac failure 39 (7.3)j 32 (7.6)k 
Pneumonia 26 (4.8) 13 (3.1) 
Dyspnea 17 (3.2) 17 (4.1) 
Syncope 14 (2.6) 10 (2.4) 
PHl 15 (2.8) 7 (1.7) 
Pulmonary embolism 3 (0.6) 9 (2.1) 
Any drug-related SAEh 13 (2.4) 21 (5.0) 
Discontinuation due to SAE 17 (3.2) 21 (5.0) 
AE, adverse event; PH, pulmonary hypertension; RV, right ventricular; SAE, serious adverse 
event. 
aReceiving riociguat for ≥ 3 months before entry. Median (range) duration of observation and 
riociguat treatment (days): 532.0 (0.0−1346.0); 506.0 (0.0−1346.0). 
bReceiving riociguat for < 3 months before entry. Median (range) duration of observation and 
riociguat treatment (days): 475.0 (0.0−1367.0); 455.0 (0.0−1367.0). 
cPreferred-term AEs reported in ≥ 5% of patients in either group. 
dIncluding peripheral edema in 46 patients (8.6%) and edema in 30 patients (5.6%). 
eIncluding peripheral edema in 27 patients (6.4%) and edema in 12 patients (2.9%). 
fIncluding RV failure in 34 patients (6.3%) and cardiac failure in 7 patients (1.3%). 
gIncluding RV failure in 27 patients (6.4%) and cardiac failure in 9 patients (2.1%). 
hInvestigator's causality assessment.  
iPreferred-term SAEs reported in ≥ 2% of patients in either group. 
jIncluding RV failure in 34 patients (6.3%) and cardiac failure in 6 patients (1.1%). 
kIncluding RV failure in 25 patients (6.0%) and cardiac failure in 9 patients (2.1%). 
lPreferred term for worsening of the condition. 













3.4. AEs and SAEs of special interest 
 In general, AEs and SAEs of special interest were infrequent (Table 5). All of the 16 
patients with serious hemoptysis/pulmonary hemorrhage overall were recorded as receiving 
concomitant anticoagulants, three as receiving concomitant antiplatelet therapy, and one as 
receiving a concomitant prostanoid. The incidence of hypotension was low across all 
subgroups (supplementary Table 6). 
 
Table 5 
AEs and SAEs of special interest. 
 All CTEPH 
(n = 956)a 
Riociguat-
pretreatedb 
(n = 537) 
Riociguat- 
newly treatedc 
(n = 419) 
















































AE, adverse event; CI, confidence interval; CTEPH, chronic thromboembolic pulmonary 
hypertension; SAE, serious adverse event. 
aMedian (range) duration of observation and riociguat treatment (days): 504.0 (0.0−1367.0); 
493.5 (0.0−1367.0). 
bReceiving riociguat for ≥ 3 months before entry. Median (range) duration of observation and 
riociguat treatment (days): 532.0 (0.0−1346.0); 506.0 (0.0−1346.0). 
cReceiving riociguat for < 3 months before entry. Median (range) duration of observation and 











dRate per 100 patient-years, calculated by the number of events observed divided by (total 
drug exposure in years/100). 
3.5. AEs associated with PEA or BPA 
 In total, 47 patients (4.9%) underwent PEA (one operation in 44 patients [4.6%] and two 
operations in three patients [0.3%]). Within 10 days after PEA, nine of these patients (19.1%) 
had an AE, six (12.8%) had an SAE, and one (2.1%) had an AE-related death. No episode 
of hemoptysis was reported within 10 days following PEA. Also, 89 patients (9.3%) 
underwent BPA (mean: 2.1 ± 1.4 sessions; median: 2; range: 1−8) during the study. Within 
10 days after BPA, six of these patients (6.7%) had an AE and six (6.7%) had an SAE. No 
AE-related deaths were reported. The AEs included hemoptysis in two patients. Both events 
resolved, and neither was considered related to riociguat. None of the AEs reported within 
10 days after PEA or BPA was considered related to riociguat. 
3.6. Efficacy assessments 
 Results for indicators of efficacy (6MWD, Borg Dyspnea Index, EQ-5D VAS, 
hemodynamic measurements, and biomarkers) have not been the focus of this non-
interventional study; many data were missing, and values varied greatly between patients. 
Selection bias for repeat efficacy assessments could confound the results. These results are 
therefore not shown or discussed here. 
3.7. Deaths and fatal SAEs 
Of the 956 patients with CTEPH, 101 (10.6%) (44 riociguat-newly treated patients 
[10.5%] and 57 riociguat-pretreated patients [10.6%]) died or experienced an SAE with a 
fatal outcome with onset during the study. Of these SAEs, 93 (9.7% of patients) began 
during the treatment phase: 38 in riociguat-newly treated patients (9.1%) and 55 in riociguat-
pretreated patients (10.2%). Fatal SAEs with post-treatment onset occurred in six riociguat-











common fatal SAEs in the total CTEPH population were RV failure/cardiac failure in 27 
patients (2.8%), followed by cardiac arrest, pneumonia, sepsis, and hemoptysis, each in 
three patients (0.3%). In 19 patients (2.0%), the SAE was listed as death (cause unknown). 
Two deaths were considered related to riociguat by the investigator. In one case the cause 
of death was hemoptysis, which occurred more than 2 years after therapy was initiated in a 
patient receiving concurrent anticoagulant medication. The other case was death from RV 
failure/cardiac failure, which occurred 10 days after the last dose of riociguat and was 
attributed to lack of efficacy of riociguat rather than an AE of the drug. 
Estimated survival rates in the total CTEPH population at 1, 2, and 3 years were 94.7% 
(95% CI, 92.9−96.0%), 85.7% (95% CI, 82.4−88.4%), and 79.3% (95% CI, 74.0−83.6%), 
respectively. Kaplan−Meier survival curves for riociguat-newly treated and riociguat-
pretreated patients are shown in Figure 4. 
 
 












CI, confidence interval. 
 
In the post hoc analysis assessing patients according to disease duration, death during 
the treatment period occurred in 77 prevalent patients (10.8%) and 14 incident patients 




4.1. Safety findings 
EXPERT provided data on the safety and tolerability of riociguat in more than 950 
patients with CTEPH in real-world clinical practice. The types of AEs observed were 
consistent with those reported in Chronic Thromboembolic Pulmonary Hypertension Soluble 
Guanylate Cyclase–Stimulator Trial-1 (CHEST-1) [14], CHEST-2 [15, 17], and the CTEPH 
Early Access Study [18], with no new safety signals identified. The most common events 
(e.g., peripheral edema/edema, dizziness, and dyspnea) were consistent with symptoms of 
the underlying disease or with vasodilatation by riociguat. Although the numbers of patients 
undergoing BPA or PEA were small, there was no evidence of an increased risk of drug-
related events shortly after these procedures. The exposure-adjusted rate of hypotension 
(2.7 events per 100 patient-years) was lower than that reported in CHEST-2 (4.0 events per 
100 patient-years) [15]. The rates of hemoptysis/pulmonary hemorrhage were similar (2.2 
and 2.8 events per 100 patient-years in EXPERT and CHEST-2 [15] respectively). Most 
patients were receiving anticoagulants as required by CTEPH treatment guidelines: these 
may have contributed to the bleeding AEs. A separate publication comparing hemorrhagic 
and thrombotic/embolic events in patients receiving VKAs or NOACs at baseline is in 
preparation. In patients receiving riociguat as part of a combination regimen, the incidences 











interpreted with caution as they are descriptive, they are not adjusted for differences 
between the combination and monotherapy groups, they refer to treatment at baseline, and 
the numbers of patients receiving prostanoids were small. Clinical experience with riociguat 
shows an increased frequency of some AEs such as hypotension, dizziness, and edema 
during dose adjustment [19, 20]. These effects, described in the reference safety information 
for the drug, have been attributed to the vasodilatory properties of riociguat [19]. Although 
the overall frequency of AEs or SAEs did not differ greatly between riociguat-newly treated 
and riociguat-pretreated patients, numerically more events of hypotension were reported in 
newly treated patients, as was discontinuation because of AEs or SAEs. The higher 
frequency of hypotension might be partly explained by a more severe disease state (as 
indicated by 6MWD and WHO FC) and partly by more frequent monitoring during dose-
adjustment periods. For riociguat-pretreated patients, bias may be introduced, because 
those who had to discontinue the drug because of AEs, or who died, could not be 
documented in the study. Patients enrolled in disease registries as prevalent cases may be 
more likely to have stable disease than incident patients [21]. In our post hoc analysis, rates 
of AEs and SAEs were similar between prevalent and incident patients, indicating that the 
higher proportion of incident patients in the riociguat-newly treated group did not 
disadvantage them in terms of safety. There is no explanation for the greater number of 
deaths in prevalent patients than incident patients but it may be related to the longer CTEPH 
disease duration in the prevalent group. 
 
4.2. Comparison with other studies 
Compared with the 247 non-operable patients described in the international prospective 
CTEPH registry [8, 22], CTEPH patients in EXPERT had less severe functional impairment, 
with 53.1% categorized as WHO FC III/IV at baseline versus 83.0% and a slightly higher 
mean 6MWD at baseline (365 vs. 315 m). The international registry enrolled only incident 











prospective study of 392 patients newly diagnosed with CTEPH in Germany, riociguat was 
the initial treatment in 81.1% of patients who received medical therapy, illustrating the 
importance of obtaining safety data for riociguat [23]. The patients in this study had generally 
similar characteristics to those in the EXPERT population.  
The estimated survival rate in patients with CTEPH in EXPERT (94.7%, 85.7%, and 
79.3% at 1, 2, and 3 years, respectively) appears to be higher than in non-operable patients 
in the international CTEPH registry (88%, 79%, and 70% at 1, 2, and 3 years, respectively) 
[22], non-PEA patients in the Giessen registry (84.5% at 1 year and 72.5% at 3 years) [24], 
US veterans evaluated in a retrospective analysis (89.2%, 81.4%, and 72.7% at 1, 3, and 5 
years, respectively) [25], and patients in several other registries [12, 13, 24, 26–28]. In an 
analysis from COMPERA, 561 medically treated patients with CTEPH were graded as at 
low, intermediate, or high risk for death based on their WHO FC, 6MWD, BNP/NT-proBNP, 
RAP, CI, and SVO2 [29]. The estimated 1-year survival rate was 98.6%, 94.9%, and 75.5% 
in the low-, intermediate-, and high-risk groups, respectively. The baseline characteristics of 
CTEPH patients in EXPERT and their estimated survival were closest to those of the 
intermediate-risk COMPERA group.  
Registries provide important information about the safety of drugs in clinical practice and 
thus supplement the information gained from selected populations under the closely 
controlled conditions of clinical trials. They may also detect previously unsuspected safety 
signals. No such signals were identified in EXPERT. Limitations inherent in registries 
including confounding, lack of randomization, missing values, and the hazards of 
generalizing data from the registry population to other populations [30], also apply to 
EXPERT. In addition, EXPERT was designed to collect safety information on riociguat; it 
was not designed to provide data on the long-term efficacy of this drug. Strengths of 
EXPERT include the relatively long observation time (median: 504 days), the large number 
(956) of patients with CTEPH, the large proportion of patients completing the study. The 











≥ 3 “uncommon” AEs with an incidence ≥ 0.5%. Given that 956 patients with CTEPH were 
enrolled, there were enough patients in the CTEPH cohort alone to achieve this power level. 
The availability of safety data in patients receiving riociguat either as monotherapy or as part 
of a combination regimen at baseline was also a strength of the study. 
Conclusion 
Final data from the EXPERT registry showed that in patients with CTEPH, the long-term 
safety of riociguat in routine practice, was consistent with clinical trials, with no new safety 
concerns identified.  
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Riociguat is approved for treatment of chronic thromboembolic pulmonary hypertension (CTEPH). 
The EXPERT study evaluated the safety of riociguat in clinical practice. 
Results are available for 956 CTEPH patients in 28 countries, followed for 1−4 years. 
The safety of riociguat in clinical practice was consistent with clinical trials. 










The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients 
with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic 
thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. Information 
on the safety of riociguat in clinical practice could complement the results obtained in these trials. 
The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) was an 
international, multicenter, prospective, uncontrolled, non-interventional cohort study designed to 
obtain this information. 
EXPERT was the largest study of its kind in patients receiving riociguat for the treatment of CTEPH. It 
was performed in 28 countries in Europe, Canada, Latin America, and the Middle East. Patients 
pretreated or newly treated with riociguat, alone or in combination with PAH-approved therapies, 
were eligible for inclusion. 
This paper describes the final EXPERT data for patients with CTEPH (n=956). Patients were followed 
from 1 to 4 years from enrolment, and approximately 86% of patients completed the study, 
producing a substantial safety database. Data are presented for adverse events (AEs), serious AEs, 
AEs of special interest (hypotension and hemoptysis/pulmonary haemorrhage), and estimated 
survival in pretreated and newly treated patients. These results showed that the safety of riociguat 
in clinical practice in patients with CTEPH was consistent with the clinical trials, with no new safety 
concerns identified. The most common types of AE observed were consistent with the underlying 
disease or the known pharmacological effects of riociguat. The exposure-adjusted rate of 
hemoptysis/pulmonary hemorrhage was comparable to the long-term extension of the Phase 3 trial 
of riociguat in CTEPH. Riociguat is the only medical therapy currently licensed for the treatment of 
CTEPH: the results are therefore relevant to all clinicians involved in the pharmacological 
management of this condition. Our results could aid clinicians in making decisions about the use of 
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